BiotechTube
Giant Biogene

Giant Biogene

2367.HK
Xi'an, China· Est.
giantbiogene.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

2367.HK · Stock Price

HKD 31.36-46.69 (-59.82%)
Market Cap: $4.2B

Historical price data

Market Cap: $4.2BFounded: 2015HQ: Xi'an, China

Overview

Founded in 2015 and publicly listed in Hong Kong, Giant Biogene has established itself as a dominant force in biomaterial-based medical beauty through its proprietary human-like recombinant collagen platform. The company executes a dual-strategy, commercializing its technology via a portfolio of premium functional skincare brands and a suite of medical-grade devices for professional use. With a market capitalization of ~$29.4B, it is a standout success story, translating advanced biotech innovation into scalable commercial products for the Chinese and global markets.

Medical AestheticsDermatologyWound Care

Technology Platform

Proprietary human-like recombinant collagen production platform using engineered microbial fermentation, enabling scalable, safe, and customizable biomaterials for medical and skincare applications.

Funding History

1
IPOUndisclosed

Opportunities

The company is positioned at the forefront of the shift towards bio-engineered, sustainable biomaterials in the massive and growing global medical aesthetics and functional skincare markets.
International expansion and potential platform extension into therapeutic areas like orthopedics present significant long-term growth vectors.

Risk Factors

Key risks include regulatory dependency on the NMPA and other agencies, high concentration in the Chinese market, intense competition from both traditional and novel technologies, and execution challenges in global expansion.

Competitive Landscape

Giant Biogene competes with traditional animal-collagen and hyaluronic acid filler companies, other recombinant collagen developers, and premium skincare brands. Its primary advantage is its vertically integrated model, controlling its proprietary platform from R&D through to commercial sales.

More companies in China →